These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25135996)

  • 1. Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy.
    Atkins CD
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135996
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective.
    Chan A; Chiang J; Lew KY; Chay WY
    J Clin Oncol; 2011 Jun; 29(16):e489; author reply e490-1. PubMed ID: 21482983
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
    Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
    J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
    J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not?
    Avan A; Avan A; Giovannetti E; Peters GJ
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135990
    [No Abstract]   [Full Text] [Related]  

  • 6. [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
    Dong M; Xing PY; Liu P; Feng FY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2010 Mar; 32(3):208-11. PubMed ID: 20450590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to C.d. Atkins and a. Avan et Al.
    Loprinzi CL; Qin R; Grothey A
    J Clin Oncol; 2014 Oct; 32(29):3342-3. PubMed ID: 25135995
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcium and magnesium for oxaliplatin-induced neuropathy.
    Stansfield L
    Am J Health Syst Pharm; 2014 Jun; 71(12):987-8. PubMed ID: 24865753
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Cavaletti G
    Oncologist; 2011; 16(12):1667-8. PubMed ID: 22128117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2011 Jun; 29(18):e553-4; author reply e555-6. PubMed ID: 21606425
    [No Abstract]   [Full Text] [Related]  

  • 13. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Khattak MA
    Oncologist; 2011; 16(12):1780-3. PubMed ID: 22128115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral sensory neuropathy--fighting cold with cold.
    Castro M
    Lancet Oncol; 2008 May; 9(5):415-6. PubMed ID: 18452855
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
    Wrzesinski SH; McGurk ML; Donovan CT; Ferencz TM; Saif MW
    Anticancer Drugs; 2007 Jul; 18(6):721-4. PubMed ID: 17762403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.
    Pachman DR; Ruddy K; Sangaralingham LR; Grothey A; Shah ND; Beutler AS; Hubbard JM; Loprinzi CL
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1097-101. PubMed ID: 26358793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New data question treatment for oxaliplatin neurotoxicity.
    Wolf SL
    Clin J Oncol Nurs; 2008 Feb; 12(1):14; author reply 14. PubMed ID: 18323035
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
    Chang YY; Lin JK; Jiang JK
    Colorectal Dis; 2012 Dec; 14(12):e821. PubMed ID: 22330089
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
    Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
    Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.